ICU sedation, delirium & recovery

Incidence and predictors of new persistent benzodiazepine and Z-drug use after critical illness: a nationwide cohort study

Eur J AnaesthesiolPublished Retrospective cohort study

Authors' conclusion

Nearly one in six ICU survivors developed new persistent BZRA use. Along with psychiatric comorbidities and female sex, pre-ICU exposure to SSRIs and opioids identified patients at particularly high risk.

Study context

Population
BZRA-naive adults (≥ 18 years) admitted to any ICU in the Republic of Korea, 2020–2022, surviving at least 180 days
Participants
620,810 adults
Outcome
New persistent BZRA use (≥ 4 consecutive weeks of BZRA prescriptions, refill gaps ≤ 7 days)
Follow-up
6 months after index ICU admission
Methodological detailspopulation-based, nationwide claims data
  • Population-based
  • Nationwide claims data

Main finding

As reported in the abstract

New persistent BZRA use · 6 months

Patients meeting criteria for new persistent BZRA use

94 293

15.2%

Observational data: associations, not effects.

Further findings

Predictors of new persistent BZRA use (multivariable logistic regression)

OR (95% CI)P value
Pre-ICU SSRI use1.78 (1.74–1.82)P < 0.001
Pre-ICU opioid use1.41 (1.38–1.43)P < 0.001
Insomnia2.06 (2.00–2.11)P < 0.001
Anxiety1.55 (1.51–1.59)P < 0.001
Depression1.32 (1.28–1.36)P < 0.001
Bipolar disorder1.27 (1.23–1.30)P < 0.001
Female sex1.23 (1.21–1.24)
Medical Aid status (socioeconomic disadvantage)1.06 (1.03–1.10)
ECMO support1.07 (1.03–1.12)
  • Predictors of new persistent BZRA use (multivariable logistic regression): psychiatric disorders adjusted for pre-ICU selective serotonin reuptake inhibitor (SSRI) and opioid use

Original publication

Incidence and predictors of new persistent benzodiazepine and Z-drug use after critical illness: a nationwide cohort study. Eur J Anaesthesiol. Published 24 March 2026. doi:10.1097/eja.0000000000002395

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.